Trinity Biotech (NASDAQ:TRIB) Now Covered by StockNews.com

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note published on Thursday morning. The firm issued a buy rating on the stock.

Trinity Biotech Stock Performance

Shares of NASDAQ TRIB opened at $1.80 on Thursday. The stock’s 50-day moving average is $2.02 and its two-hundred day moving average is $2.20. Trinity Biotech has a 1-year low of $1.66 and a 1-year high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings results on Thursday, April 4th. The company reported ($0.68) earnings per share for the quarter. The business had revenue of $13.43 million during the quarter. Sell-side analysts expect that Trinity Biotech will post -1.5 EPS for the current fiscal year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.